JPMorgan Lowers Brenntag Price Target to EUR 44, Maintains Underweight Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
- Price Target Adjustment: JPMorgan has lowered its price target for Brenntag from EUR 45.40 to EUR 44, reflecting a cautious outlook on the company's future performance, which may lead to decreased investor confidence.
- Rating Maintained: Despite the price target reduction, JPMorgan maintains an Underweight rating on Brenntag, indicating analysts' conservative view on the stock's long-term performance, which could affect market demand for the shares.
- Market Reaction Anticipation: This adjustment may prompt a reevaluation of Brenntag's stock in the market, as investors might reconsider their holding strategies due to the lowered price target, potentially impacting short-term stock price volatility.
- Industry Impact: As a key player in the chemical distribution sector, the price target reduction for Brenntag could have a ripple effect on investor sentiment across the industry, particularly in the context of the current uncertain economic environment.
Analyst Views on BNR
About BNR
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
